Seizures in Alzheimer's disease

Neuroscience

Volumn 286, Issue , 2015, Pages 251-263

  Born, H A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid ; Antiepileptic therapy; Mouse models; Seizures

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTICONVULSIVE AGENT; PRESENILIN 1; PRESENILIN 2; APP PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMNESIA; APP GENE; BRAIN CORTEX; BRAIN ELECTROPHYSIOLOGY; COGNITIVE DEFECT; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; FAMILIAL DISEASE; GENE DUPLICATION; GENE MUTATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MYOCLONUS SEIZURE; NERVE CELL NETWORK; NERVE EXCITABILITY; NONHUMAN; ONSET AGE; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PSEN1 GENE; PSEN2 GENE; REVIEW; SEIZURE; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SEIZURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; HUMANS; MICE; NERVE NET; NEURONS; RISK FACTORS; SEIZURES;

EID: 84921292800     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.11.051     Document Type: Review

References (124)

1. Alberici A., Bonato C., Borroni B., Cotelli M., Mattioli F., Binetti G., Gennerlli M., Luca M.D., Simonati A., Perani D., Rossini P., Padovani A. Dementia, delusions and seizures: storage disease or genetic AD?. Eur J Neurol 2007, 14:1057-1059.
2. Alper K.R., Barry J.J., Balabanov A.J. Treatment of psychosis, aggression, and irritability in patients with epilepsy. Epilepsy Behav 2002, 3:13-18.
3. Amatniek J.C., Hauser W.A., DelCastillo-Castaneda C., Jacobs D.M., Marder K., Bell K., Albert M., Brandt J., Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006, 47:867-872.
4. Armon C., Shin C., Miller P., Carwile S., Brown E., Edinger J., Paul R. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996, 47:626-635.
5. Bakker A., Krauss G., Albert M., Speck C., Jones L., Stark C., Yassa M., Bassett S., Shelton A., Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012, 74:467-474.
6. Belcastro V., Costa C., Galletti F., Pisani F., Calabresi P., Parnetti L. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol 2007, 14:1176-1178.
7. Bell K.F., Ducatenzeiler A., Ribeiro-da-Silva A., Duff K., Bennett D.A., Cuello A.C. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 2006, 27:1644-1657.
8. Bomben V., Holth J., Reed J., Cramer P., Landreth G., Noebels J. Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol Aging 2014, 35:2091-2095.
9. Born H.A., Kim J.Y., Savjani R.R., Das P., Dabaghian Y.A., Guo Q., Yoo J.W., Schuler D.R., Cirrito J.R., Zheng H., Golde T.E., Noebels J.L., Jankowsky J.L. Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci 2014, 34:3826-3840.
10. Busche M.A., Chen X., Henning H.A., Reichwald J., Staufenbiel M., Sakmann B., Konnerth A. Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2012, 109:8740-8745.
11. Busche M.A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K.H., Haass C., Staufenbiel M., Konnerth A., Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008, 321:1686-1689.
12. Cabrejo L., Guyant-Maréchal L., Laquerrière A., Vercelletto M., De la Fournière F., Thomas-Antérion C., Verny C., Letournel F., Pasquier F., Vital A., Checler F., Frebourg T., Campion D., Hannequin D. Phenotype associated with APP duplication in five families. Brain 2006, 129:2966-2976.
13. Caillé I., Allinquant B., Dupont E., Bouillot C., Langer A., Müller U., Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 2004, 131:2173-2181.
14. Campion D., Brice A., Dumanchin C., Puel M.I., Baulac M., De La Sayette V., Mannequin D., Duyckaerts C., Michon A.S., Martin C. A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29years. NeuroReport 1996, 7:1582-1584.
15. Campion D., Dumanchin C., Hannequin D., Dubois B., Belliard S., Puel M., Thomas-Anterion C., Michon A., Martin C., Charbonnier F., Raux G., Camuzat A., Penet C., Mesnage V., Martinez M., Clerget-Darpoux F., Brice A., Frebourg T. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999, 65:664-670.
16. Caviness J.N., Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004, 3:598-607.
17. Chin J., Scharfman H.E. Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. Epilepsy Behav 2013, 26:343-351.
18. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 2005, 48:913-922.
19. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat Neurosci 2005, 8:79-84.
20. Cloyd J., Hauser W., Towne A., Ramsay R., Mattson R., Gilliam F., Walczak T. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res 2006, 68(Suppl. 1):S39-S48.
21. Corbett B.F., Leiser S.C., Ling H.P., Nagy R., Breysse N., Zhang X., Hazra A., Brown J.T., Randall A.D., Wood A., Pangalos M.N., Reinhart P.H., Chin J. Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 2013, 33:7020-7026.
22. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.D., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
23. Cumbo E., Ligori L.D. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav 2010, 17:461-466.
24. de Groot M., Douw L., Sizoo E.M., Bosma I., Froklage F.E., Heimans J.J., Postma T.J., Klein M., Reijneveld J.C. Levetiracetam improves verbal memory in high-grade glioma patients. Neuro-oncology 2013, 15:216-223.
25. Del Vecchio R., Gold L., Novick S., Wong G., Hyde L. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett 2004, 367:164-167.
26. Devi G., Fotiou A., Jyrinji D., Tycko B., DeArmand S., Rogaeva E., Song Y.-Q., Medieros H., Liang Y., Orlacchio A. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch Neurol 2000, 57:1454-1457.
27. Devi L., Ohno M. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. Neurobiol Learn Mem 2013, 102:7-11.
28. Doran M., Larner A. Prominent behavioural and psychiatric symptoms in early-onset Alzheimer's disease in a sib pair with the presenilin-1 gene R269G mutation. Eur Arch Psychiatry Clin Neurosci 2004, 254:187-189.
29. Edwards-Lee T., Ringman J.M., Chung J., Werner J., Morgan A., St George Hyslop P., Thompson P., Dutton R., Mlikotic A., Rogaeva E., Hardy J. An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 2005, 64:377-379.
30. Ezquerra M., Carnero C., Blesa R., Gelpi J., Ballesta F., Oliva R. A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures. Neurology 1999, 52. 566-566.
31. Ezquerra M., Lleó A., Castellví M., Queralt R., Santacruz P., Pastor P., Molinuevo J.L., Blesa R., Oliva R. A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. Arch Neurol 2003, 60:1149-1151.
32. Ferrendelli J., French J., Leppik I., Morrell M., Herbeuval A., Han J., Magnus L. Use of levetiracetam in a population of patients aged 65years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003, 4:702-709.
33. Fleisher A.S., Truran D., Mai J.T., Langbaum J.B., Aisen P.S., Cummings J.L., Jack C.R., Weiner M.W., Thomas R.G., Schneider L.S., Tariot P.N. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011, 77:1263-1271.
34. Flood J.F., Morley J.E., Roberts E. Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1991, 88:3363-3366.
35. Forsgren L., Bucht G., Eriksson S., Bergmark L. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996, 37:224-229.
36. Fowler S.W., Chiang A.C., Savjani R.R., Larson M.E., Sherman M.A., Schuler D.R., Cirrito J.R., Lesné S.E., Jankowsky J.L. Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci 2014, 34:7871-7885.
37. Furuya H., Yasuda M., Terasawa K.-J., Tanaka K., Murai H., Kira J.I., Ohyagi Y. A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion. J Neurol Sci 2003, 209:75-77.
38. Gakhar-Koppole N., Hundeshagen P., Mandl C., Weyer S., Allinquant B., Müller U., Ciccolini F. Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur J Neurosci 2008, 28:871-872.
39. Guo Q., Li H., Cole A.L., Hur J.-Y., Li Y., Zheng H. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and Tau. PLoS One 2013, 8:e80706.
40. Guo Q., Li H., Gaddam S., Justice N., Robertson C., Zheng H. Amyloid precursor protein revisited: neuron-specific expression and highly stable nature of soluble derivatives. J Biol Chem 2012, 287:2437-2445.
41. Guo Q., Zheng H., Justice N.J. Central CRF system perturbation in an Alzheimer's disease knockin mouse model. Neurobiol Aging 2012, 33:2678-2691.
42. Hauser W., Morris M., Heston L., Anderson V. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986, 36:1220-1226.
43. Hesdorffer D., Hauser W., Annegers J., Kokmen E., Rocca W. Dementia and adult-onset unprovoked seizures. Neurology 1996, 46:727-730.
44. Hoe H.S., Lee H.K., Pak D.T. The upside of APP at synapses. CNS Neurosci Ther 2012, 18:47-56.
45. Holsinger R.M.D., McLean C.A., Beyreuther K., Masters C.L., Evin G. Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann Neurol 2002, 51:783-786.
46. Houlden H., Crook R., Dolan R., McLaughlin J., Revesz T., Hardy J. A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies. Neurosci Lett 2001, 313:93-95.
47. Hsiao K., Borchelt D., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
48. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
49. Ikeda M., Sharma V., Mark Sumi S., Rogaeva E.A., Poorkaj P., Sherrington R., Nee L., Tsuda T., Oda N., Watanabe M. The clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients. Ann Neurol 1996, 40:912-917.
50. Irizarry M.C., Jin S., He F., Emond J.A., Raman R., Thomas R.G., Sano M., Quinn J.F., Tariot P.N., Galasko D.R., Ishihara L.S., Weil J.G., Aisen P.S. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 2012, 69:368-372.
51. Ito M., Echizenya N., Nemoto D., Kase M. A case series of epilepsy-derived memory impairment resembling Alzheimer disease. Alzheimer Dis Assoc Disord 2009, 23:406-409.
52. James B.D., Leurgans S.E., Hebert L.E., Scherr P.A., Yaffe K., Bennett D.A. Contribution of Alzheimer disease to mortality in the United States. Neurology 2014.
53. Janssen J., Beck J., Campbell T., Dickinson A., Fox N., Harvey R., Houlden H., Rossor M., Collinge J. Early onset familial Alzheimer's disease mutation frequency in 31 families. Neurology 2003, 60:235-239.
54. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
55. Jayadev S., Leverenz J., Steinbart E., Stahl J., Klunk W., Yu C., Bird T. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 2010, 133:1143-1154.
56. Jolas T., Zhang X., Zhang Q., Wong G., Del Vecchio R., Gold L., Priestley T. Long-term potentiation is increased in the CA1 area of the hippocampus of APP(swe/ind) CRND8 mice. Neuorobiol Dis 2002, 11:394-409.
57. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
58. Kennedy A.M., Newman S., McCaddon A., Ball J., Roques P., Mullan M., Hardy J., Chartier-Harlin M.C., Frackowiak R.S., Warrington E.K., et al. Familial Alzheimer's disease. A pedigree with a mis-sense mutation in the amyloid precursor protein gene (amyloid precursor protein 717 valine→glycine). Brain 1993, 116(Pt. 2):309-324.
59. LaFerla F.M., Tinkle B.T., Bieberich C.J., Haudenschild C.C., Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 1995, 9:21-30.
60. Lai F., Williams R.S. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989, 46:849-853.
61. Lalonde R., Dumont M., Staufenbiel M., Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res 2005, 157:91-98.
62. Larner A. Epileptic seizures in AD patients. NeuroMol Med 2009, 12:71-77.
63. Larner A., Ray P., Doran M. The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer's disease. J Neurol Sci 2007, 252:173-176.
64. Li H., Wang B., Wang Z., Guo Q., Tabuchi K., Hammer R., Südhof T., Zheng H. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci U S A 2010, 107:17362-17367.
65. Lindquist S.G., Nielsen J.E., Stokholm J., Schwartz M., Batbayli M., Ballegaard M., Erdal J., Krabbe K., Waldemar G. Atypical early-onset Alzheimer's disease caused by the Iranian APP mutation. J Neurol Sci 2008, 268:124-130.
66. Lippa C.F., Swearer J.M., Kane K.J., Nochlin D., Bird T.D., Ghetti B., Nee L., St George-Hyslop P., Pollen D.A., Drachman D.A. Familial Alzheimer's disease: site of mutation influences clinical phenotype. Ann Neurol 2000, 48:376-379.
67. Lleó A., Blesa R., Queralt R., Ezquerra M., Molinuevo J.L., Pena-Casanova J., Rojo A., Oliva R. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol 2002, 59:1759-1763.
68. Long Z., Zheng M., Zhao L., Xie P., Song C., Chu Y., Song W., He G. Valproic acid attenuates neuronal loss in the brain of APP/PS1 double transgenic Alzheimer's disease mice model. Curr Alzheimer Res 2013, 10:261-269.
69. Loring D.W., Marino S., Meador K.J. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 2007, 17:413-425.
70. Lozsadi D.A., Larner A.J. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement Geriatr Cogn Disord 2006, 22:121-124.
71. Marcon G., Giaccone G., Cupidi C., Balestrieri M., Beltrami C.A., Finato N., Bergonzi P., Sorbi S., Bugiani O., Tagliavini F. Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol Exp Neurol 2004, 63:199-209.
72. Martin J., Gheuens J., Bruyland M., Cras P., Vandenberghe A., Masters C., Beyreuther K., Dom R., Ceuterick C., Lübke U., Van Heuverswijn H., De Winter G., Van Broeckhoven C. Early-onset Alzheimer's disease in 2 large Belgian families. Neurology 1991, 41. 62-62.
73. Masters C., Simms G., Weinman N., Multhaup G., McDonald B., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985, 82:4245-4249.
74. Mendes M.H.F. Transient epileptic amnesia: an under-diagnosed phenomenon? Three more cases. Seizure 2002, 11:238-242.
75. Mendez M., Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003, 20:791-803.
76. Minkeviciene R., Rheims S., Dobszay M.B., Zilberter M., Hartikainen J., Fulop L., Penke B., Zilberter Y., Harkany T., Pitkanen A., Tanila H. Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 2009, 29:3453-3462.
77. Moechars D., Dewachter I., Lorent K., Rdverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Van Den Haute C., Checler F., Godaux E., Cordell B., Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999, 274:6483-6492.
78. Mohajeri M., Saini K., Schultz J., Wollmer M., Hock C., Nitsch R. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002, 277:33012-33017.
79. Morelli L., Prat M.I., Levy E., Mangone C.A., Castaño E.M. Presenilin 1 Met146Leu variant due to an A&T transversion in an early-onset familial Alzheimer's disease pedigree from Argentina. Clin Genet 1998, 53:469-473.
80. Morley J.E., Farr S.A. Hormesis and amyloid-beta protein: physiology or pathology?. J Alzheimers Dis 2012, 29:487-492.
81. Mucke L., Masliah E., Yu G., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptoxicity without plaque formation. J Neurosci 2000, 20:4050-4058.
82. Nikolaev A., McLaughlin T., O'Leary D.D.M., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-990.
83. Obregon D., Hou H., Deng J., Giunta B., Tian J., Darlington D., Shahaduzzaman M., Zhu Y., Mori T., Mattson M.P. Soluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generation. Nat Commun 2012, 3:777.
84. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G., Kreitzer A., Finkbeiner S., Noebels J.L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
85. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009, 66:435-440.
86. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13:812-818.
87. Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H.A., Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 2006, 26:7212-7221.
88. Puzzo D., Privitera L., Fa M., Staniszewski A., Hashimoto G., Aziz F., Sakurai M., Ribe E.M., Troy C.M., Mercken M., Jung S.S., Palmeri A., Arancio O. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011, 69:819-830.
89. Qing H., He G., Ly P.T., Fox C.J., Staufenbiel M., Cai F., Zhang Z., Wei S., Sun X., Chen C.H., Zhou W., Wang K., Song W. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008, 205:2781-2789.
90. Queralt R., Ezquerra M., Lleó A., Castellvi M., Gelpi J., Ferrer I., Acarín N., Pasarín L., Blesa R., Oliva R. A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances. J Neurol Neurosurg Psychiatry 2002, 72:266-269.
91. Rabinowicz A.L., Starkstein S.E., Leiguarda R.C., Coleman A.E. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord 2000, 14:231-233.
92. Rae-Grant A., Blume W., Lau C., Hachinski V.C., Fisman M., Merskey H. The electroencephalogram in Alzheimer-type dementia. A sequential study correlating the electroencephalogram with psychometric and quantitative pathologic data. Arch Neurol 1987, 44:50-54.
93. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.-Q., Mucke L. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
94. Romanelli M., Morris J., Ashkin K., Coben L. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990, 47:847-850.
95. Rossor M., Newman S., Frackowiak R., Lantos P., Kennedy A. Alzheimer's disease families with amyloid precursor protein mutations. Ann N Y Acad Sci 1993, 695:198-202.
96. Rowan A., Ramsay R., Collins J., Pryor F., Boardman K., Uthman B., Spitz M., Frederick T., Towne A., Carter G. New onset geriatric epilepsy A randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005, 64:1868-1873.
97. Saito T., Matsuba Y., Mihira N., Takano J., Nilsson P., Itohara S., Iwata N., Saido T.C. Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci 2014.
98. Sanchez P., Zhu L., Verret L., Vossel K., Orr A., Cirrito J., Devidze N., Ho K., Yu G., Palop J., Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 2012.
99. Santos S.F., Pierrot N., Morel N., Gailly P., Sindic C., Octave J.N. Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. J Neurosci 2009, 29:4708-4718.
100. Scarmeas N., Honig L.S., Choi H., Cantero J., Brandt J., Blacker D., Albert M., Amatniek J.C., Marder K., Bell K., Hauser W.A., Stern Y. Seizures in Alzheimer disease: who, when, and how common?. Arch Neurol 2009, 66:992-997.
101. Scharfman H.E. "Untangling" Alzheimer's disease and epilepsy. Epilepsy Curr 2012, 12:178-183.
102. Schneider F., Baldauf K., Wetzel W., Reymann K.G. Behavioral and EEG changes in male 5xFAD mice. Physiol Behav 2014, 135:25-33.
103. Selkoe D.J., Podlisny M.B. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002, 3:67-99.
104. Sleegers K., Brouwers N., Gijselinck I., Theuns J., Goossens D., Wauters J., Del-Favero J., Cruts M., van Duijn C.M., Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006, 129:2977-2983.
105. Snider B., Norton J., Coats M., Chakraverty S., Hou C., Jervis R., Lendon C., Goate A., McKeel D.J., Morris J. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 2005, 62:12.
106. Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., Brune K., Paul S., Zhou Y., Liu F., Ni B. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004, 43:6899-6908.
107. Sulkava R. Alzheimer's disease and senile dementia of Alzheimer type. Acta Neurol Scand 1982, 65:636-650.
108. Tamayev R., Matsuda S., Arancio O., D'Adamio L. β-but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med 2012, 4:171-179.
109. Thies W., Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9:208-245.
110. Tsiouris J.A., Patti P.J., Tipu O., Raguthu S. Adverse effects of phenytoin given for late-onset seizures in adults with Down syndrome. Neurology 2002, 59:779-780.
111. Velez-Pardo C., Arellano J.I., Cardona-Gomez P., Jimenez Del Rio M., Lopera F., De Felipe J. CA1 hippocampal neuronal loss in familial Alzheimer's disease presenilin-1 E280A mutation is related to epilepsy. Epilepsia 2004, 45:751-756.
112. Verret L., Mann E., Hang G., Barth A., Cobos I., Ho K., Devidze N., Masliah E., Kreitzer A., Mody I., Mucke L., Palop J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149:708-721.
113. Vogt D.L., Thomas D., Galvan V., Bredesen D.E., Lamb B.T., Pimplikar S.W. Abnormal neuronal networks and seizures susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging 2009, 5.
114. Vossel K.A., Beagle A.J., Rabinovici G.D., Shu H., Lee S.E., Naasan G., Hegde M., Cornes S.B., Henry M.L., Nelson A.B., Seeley W.W., Geschwind M.D., Gorno-Tempini M.L., Shih T., Kirsch H.E., Garcia P.A., Miller B.L., Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 2013, 70:1158-1166.
115. Walsh D.M., Selkoe D.J. Aβ oligomers-a decade of discovery. J Neurochem 2007, 101:1172-1184.
116. Wang J., Ikonen S., Gurevicius K., van Groen T., Tanila H. Alteration of cortical EEG in mice carrying mutated human APP transgene. Brain Res 2002, 943:181-190.
117. Westmark C.J. What's hAPPening at synapses? The role of amyloid beta-protein precursor and beta-amyloid in neurological disorders. Mol Psychiatry 2013, 18:425-434.
118. Westmark C.J., Westmark O.R., Beard A.M., Hildebrandt S.M., Malter J.S. Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int J Clin Exp Pathol 2008, 1:157-168.
119. Wisniewski T., Dowjat W.K., Buxbaum J.D., Khorkova O., Efthimiopoulos S., Kulczycki J., Lojkowska W., Wegiel J., Wisniewski H.M. Frangione B (A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28years. NeuroReport 1998, 9:217-221.
120. Yang L., Wang Z., Wang B., Justice N.J., Zheng H. Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity. J Neurosci 2009, 29:15660-15668.
121. Yang L.-B., Lindholm K., Yan R., Citron M., Xia W., Yang X.-L., Beach T., Sue L., Wong P., Price D., Li R., Shen Y. Elevated [beta]-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003, 9:3-4.
122. Young-Pearse T., Bai J., Chang R., Zheng J., Loturco J., Selkoe D. A critical function for amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci 2007, 27:14459-14469.
123. Zheng H., Koo E. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegen 2011, 6:27.
124. Ziyatdinova S., Gurevicius K., Kutchiashvili N., Bolkvadze T., Nissinen J., Tanila H., Pitkanen A. Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res 2011, 94:75-85.